RocketTickers

Turning Point Therapeutics Announces FDA Clearance of Investigat

Long
NASDAQ:TPTX   None
TPTX: Turning Point Therapeutics, Inc
2022-01-20 09:00:00
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.